Session » Plenary II
- 11:30AM-1:00PM
-
Abstract Number: 1112
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
- 11:30AM-1:00PM
-
Abstract Number: 1114
Computational Drug Repositioning and 3D Skin Models Identify EGFR and PI3K Inhibitors as Anti-fibrotic Targets for Systemic Sclerosis
- 11:30AM-1:00PM
-
Abstract Number: 1117
Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
- 11:30AM-1:00PM
-
Abstract Number: 1115
Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus
- 11:30AM-1:00PM
-
Abstract Number: 1116
Peripheral Blood DNA Methylation-based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biospecimens and Data from the Osteoarthritis Initiative and Johnston County Osteoarthritis Project
- 11:30AM-1:00PM
-
Abstract Number: 1113
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study